国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2012年
5期
363-366
,共4页
蛋白质丝氨酸苏氨酸激酶%药物疗法%肿瘤
蛋白質絲氨痠囌氨痠激酶%藥物療法%腫瘤
단백질사안산소안산격매%약물요법%종류
Protein-serine-threonine kinases%Drug therapy%Neoplasms
近年来mTOR抑制剂在抗肿瘤治疗中备受瞩目,其代表药物依维莫司和坦罗莫司已在多个临床研究被证实可作为新一代的有效药物,尤其在逆转肿瘤耐药方面被寄予厚望.而mTOR抑制剂与其他抗癌药物的最佳联合方案仍需验证.
近年來mTOR抑製劑在抗腫瘤治療中備受矚目,其代錶藥物依維莫司和坦囉莫司已在多箇臨床研究被證實可作為新一代的有效藥物,尤其在逆轉腫瘤耐藥方麵被寄予厚望.而mTOR抑製劑與其他抗癌藥物的最佳聯閤方案仍需驗證.
근년래mTOR억제제재항종류치료중비수촉목,기대표약물의유막사화탄라막사이재다개림상연구피증실가작위신일대적유효약물,우기재역전종류내약방면피기여후망.이mTOR억제제여기타항암약물적최가연합방안잉수험증.
In recent years,mTOR inhibitors such as temsirolimus and everolimus are considered to be effective as a new generation of anti-tumor agent.Their efficacies are proven by a number of clinical trials especially in the field of overcoming the drug resistance of tumor cells.But the optimal combination regimen of the mTOR inhibitors and other anti-tumor drugs is still to be validated.
